- In November 2024, Medtronic plc received FDA clearance for its InPen app, which now features a missed meal dose detection function. This enhancement supports the company’s plan to introduce its Smart MDI system integrated with the Simplera continuous glucose monitor (CGM). This development marks a significant step toward more intelligent and responsive diabetes management
- In January 2024, Abbott and Tandem Diabetes Care, Inc. announced the integration of the t:slim X2 insulin pump with Control-IQ technology and Abbott's FreeStyle Libre 2 Plus sensor in the U.S. market. This hybrid closed-loop system helps users manage and prevent both hyperglycemia and hypoglycemia. This collaboration enhances automated insulin delivery, improving patient outcomes
- In April 2023, Insulet Corporation obtained FDA clearance for its Omnipod GO, a wearable insulin delivery device tailored for adults with type 2 diabetes who require long-acting insulin. The device offers a more user-friendly alternative to conventional daily injection methods. This innovation provides greater convenience and adherence for individuals managing type 2 diabetes
- In February 2023, Dexcom officially launched the Dexcom G7 continuous glucose monitoring (CGM) system in the U.S., with planned expansions into Europe and Asia-Pacific scheduled for the first quarter of 2024. This launch broadens access to advanced CGM technology across global markets
- In October 2022, Abbott Laboratories introduced the Freestyle Libre 3 CGM device globally, offering real-time glucose tracking in a compact and easy-to-use format. This global release demonstrates Abbott’s continued leadership in continuous glucose monitoring innovation
